• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Omada Health Raises $192M for Chronic Care Management Tool

Share:

February 28, 2022

Digital chronic care management company Omada Health scored a whopping $192 million in Series E funding. This new infusion of cash brings the company’s total raise to more than $256 million, according to Crunchbase.

The round was led by Fidelity Management & Research Company with participation from aMoon, Perceptive Advisors, Wellington Management, Civilization Ventures, and others.

WHAT THEY DO

Founded in 2011, Omada got its start in prediabetes management. However, today the company’s services include management for diabetes, hypertension, and musculoskeletal (MSK) conditions.

The San Francisco-based company is focused on aiding individuals in managing their own health conditions through personalized data-driven behavior change coaching. The platform can help users keep track of their diet, exercise, blood glucose, and other metrics. Patients can also access virtual care for support.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In 2020 the company acquired MSK-focused Physera, which gave it a foot holding in the physical therapy space. Since then the company rolled out new computer vision technology to help physical therapists virtually measure a patient’s movement and range of motion.

The company created the Omada Insights Lab, which uses clinical design, care delivery, product design, data science, and behavioral science to help develop personal goals and plans for patients.

WHAT IT’S FOR

Omada’s plans to use the Series E-money to hire more staff across the company. It also plans on building out its tech plan for care and personalization and investing in Omada Insights Lab.

“With a 10-year track record, Omada’s approach is delivering outcomes that outpace the industry,” Sean Duffy, co-founder, and CEO of Omada Health said in a statement. This latest round of funding not only validates but accelerates our mission in offering virtual chronic care treatment to millions of people across the U.S. With the support of our investors, Fidelity, aMoon, Civilization Ventures, and others, we’re able to better support our customer growth and usher in a new model of care.”

THE LARGER TREND

Chronic care management is a popular sector in digital health. One of the other major players in this space is diabetes-focused Virta, which scored $133 million in Series E funding in the Spring of 2021. Virta claims that its platform can help users “reverse diabetes.”

In 2020 telehealth company Teladoc scooped up chronic care management company Livongo for a whopping $18.5 billion.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Japanese Startup AI Medical Secures FDA Approval for Real-Time Endoscopic AI PlatformJapanese Startup AI Medical Secures FDA Approval for Real-Time Endoscopic AI Platform
  • Curebase Teams up with AppliedVR on Pain Treatment and Other Digital Health DealsCurebase Teams up with AppliedVR on Pain Treatment and Other Digital Health Deals
  • Cigna Ends Acquisition Talks with Humana, Announces $10B Share Repurchase PlanCigna Ends Acquisition Talks with Humana, Announces $10B Share Repurchase Plan
  • PharmaDrug Inc. Closes Acqusition of Securedose SyntheticsPharmaDrug Inc. Closes Acqusition of Securedose Synthetics
  • Blockchain in the revenue cycle: What healthcare needs to succeedBlockchain in the revenue cycle: What healthcare needs to succeed
  • Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive DisorderOtsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
  • TheracosBio Extends Partnership with Mark Cuban Cost Plus Drug CompanyTheracosBio Extends Partnership with Mark Cuban Cost Plus Drug Company
  • DarioHealth Launches Digital Diabetes Program on Walmart.comDarioHealth Launches Digital Diabetes Program on Walmart.com

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications